Screening for synchronous metastases in colorectal cancer with DW-MRI
IRAS Number: 135981
CPMS ID: 17059
ClinicalTrials.gov ID: NCT02246634
Trial Start Date: Aug-14
Recruitment End Date: Dec-26
Trial End date: Aug-31
It has recently been suggested that limited MRI of the liver can identify most spread to the liver. We therefore wish to test whether an additional quick MRI scan of the liver at regular intervals for patients with bowel cancer can identify spread to the liver better than the current standard of only a CT scan.
A phase II multicentre, interventional study, SERENADE will determine if additional staging at diagnosis with liver DW-MRI will diagnose more synchronous metastases than CT alone in patients with high risk colorectal cancer. Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local policy.
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.
Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.
The SERENADE trial is open to new sites.
Please fill in the form below if you would like further information or have any questions about any aspect of the trial.
